|
| [ ]
|
|
| , (n)
| , (n)
| ()
| ()
| (%)
| (n)
| (n)
| Detsky
| (%)
|
|
|
| IRMA-2 [20]
|
|
|
|
| 2,00
|
|
|
|
|
|
| , 2
|
|
| RENAAL [21]
|
|
|
|
| 3,40
|
|
|
|
|
|
|
|
|
| IDNT [22]
|
|
|
|
| 2,60
|
|
|
|
|
|
| 2
|
|
| Kondo et al. [23]
|
|
|
|
| 2,00
|
|
|
|
|
|
|
|
|
| SCOPE [24]
|
|
|
|
| 3,70
|
|
|
|
|
|
| MMSE >24
|
|
| DIRECT-PREVENT-1 [17]
|
|
|
|
| 4,70
|
|
|
|
|
|
| , 1
|
|
| DIRECT-PROTECT-1 [17]
|
|
|
|
| 4,80
|
|
|
|
|
|
| , 1
|
|
| DIRECT-PROTECT-2 [18]
|
|
|
|
| 4,70
|
|
|
|
|
|
| 2 ,
|
|
| PROFESS [26]
|
|
|
|
| 2,50
|
|
|
|
|
| NA
| ,
|
|
| TRANSCEND [27]
|
|
|
|
| 4,67
|
|
|
|
|
|
| ,
|
|
| NAVIGATOR [28]
|
|
|
|
| 6,50
|
|
|
|
|
|
|
|
|
| ORIENT [25]
|
|
|
|
| 3,20
|
|
|
|
|
|
| 2
|
|
| ROADMAP [29]
|
|
|
|
| 3,20
|
|
| NA
|
|
|
| 2
|
|
| Lewis et al. [33]
|
|
|
|
| 3,00
|
|
|
|
|
| NA
|
|
|
| AIPRI [34]
|
|
|
|
| 3,00
|
|
|
| NA
|
| NA
|
|
|
| HOPE [1]
|
|
|
|
| 5,00
|
|
|
|
|
|
| +
|
|
| PART-2 [5]
|
|
|
|
| 4,70
|
|
| NA
|
|
|
|
|
|
| SCAT [6]
|
|
|
|
| 3,98
|
|
|
|
|
|
|
|
|
| PROGRESS [3]
|
|
|
|
| 4,00
|
|
|
|
|
|
| ,
|
|
| QUIET [7]
|
|
|
|
| 3,00
|
|
|
|
|
|
|
|
|
| EUROPA [4]
|
|
|
|
| 4,20
|
|
|
|
|
|
|
|
|
| PEACE [8]
|
|
|
|
| 4,80
|
|
|
|
|
|
|
|
|
| CAMELOT [9]
|
|
|
|
| 2,00
|
|
|
|
|
|
|
|
|
| DIABHYCAR [10]
|
|
|
|
| 4,00
|
|
|
|
|
|
| 2
|
|
| DREAM [11]
|
|
|
|
| 3,00
|
|
|
|
|
| NA
| ,
|
|
| IMAGINE [12]
|
|
|
|
| 2,95
|
|
|
|
|
|
|
|
- , - , - , - , - , - ; - - ; - ; - ; - -; NA - ; AIPRI - Angiotensin-converting enzyme Inhibition in Progressive Renal Insufficiency; CAMELOT - Comparison of AMlodipine vs Enalapril to Limit Occurrences of Thrombosis; DIABHYCAR - type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril; DIRECT - DIabetic REtinopathy Candesartan Trials; DREAM - Diabetes REduction Assessment with ramipril and rosiglitazone Medication; EUROPA - in the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease; HOPE - Heart Outcomes Prevention Evaluation; PART-2 - Prevention of Atheroslerosis with Ramipril Trial; IDNT - Irbesartan Diabetic Nephropathy Trial; IMAGINE - Ischemia Management with Accupril post-bypass Graft via Inhibition of the coNverting Enzyme; IRMA-2 - IRbesartan MicroAlbuminuria type 2 diabetes mellitus in hypertensive patients; MMSE - Mini Mental State Examination; NAVIGATOR - Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research; ORIENT - Olmesartan Reducing Incidence of End stage renal disease in diabetic Nephropathy Trial; PEACE - Prevention of Events with Angiotensin Converting Enzyme inhibition; PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes; PROGRESS - Perindopril pROtection aGainst REcurrent Stroke Study; QUIET - QUinapril Ischemic Event Trial; RENAAL - Reduction in ENdpoints with the Angiotensin Antagonist Losartan; ROADMAP - Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention; SCAT - Simvastatin/enalapril Coronary Atheroslerosis Trial; SCOPE - Study on Cognition and Prognosis in the Elderly; TRASCEND - Telmisartan Randomised AssessmeNT Study in ACEiNtoleran subjects with cardiovascular Disease
2.
